Fig. 6From: Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysisComparing with initial value, there was a decline in TSH at 3 month (a) but unchangeable at 12 (b) month after RTX treatment for TAOBack to article page